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 47 
What is already known about this subject 48 
• Newly-graduated doctors prescribe medicines frequently and write a large proportion of prescriptions 49 
in UK hospitals but recent studies suggest that around one in ten of their prescriptions may contain 50 
errors 51 
• The ability to prescribe safely and effectively is one of the competencies identified as a key outcome of 52 
undergraduate medical education by the General Medical Council (the UK medical regulator) 53 
• There has been significant variation in the assessments used by medical schools to ensure that medical 54 
students have attained the necessary competence prior to graduation  55 
• Prescribing is a complex skill to assess because of the number of prescribing scenarios that might be 56 
tested, the variety of documentation used and the challenge of marking large numbers of prescriptions 57 
in a standardised way 58 
 59 
What this study adds 60 
• The Prescribing Safety Assessment (PSA) has been developed as a 2-hour online assessment of 61 
competence in relation to prescribing and supervising the use of medicines in a modern healthcare 62 
setting 63 
• The PSA delivers a standard national prescribing assessment involving around two hundred assessment 64 
events at academic centres around the UK (and overseas) each year and enables large numbers of 65 
prescriptions (around 60,000) to be instantaneously assessed against a standardised marking scheme 66 
• There was significant variation in the performance of cohorts of students from different medical 67 
schools  68 
• The vast majority of UK final-year medical students were able to meet the pre-specified standard of 69 
competence as defined by the PSA pass mark 70 
 71 
72 
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Summary 73 
Aim(s). Newly graduated doctors write a large proportion of prescriptions in UK hospitals but recent studies 74 
have shown that they frequently make prescribing errors. The Prescribing Safety Assessment (PSA) has 75 
been developed as an assessment of competence in relation to prescribing and supervising the use of 76 
medicines. This report describes the delivery of the PSA to all UK final-year medical students in 2016 77 
(PSA2016).  78 
Methods. The PSA is a 2-hour online assessment comprising eight sections which cover various aspects of 79 
prescribing defined within the outcomes of undergraduate education identified by the UK General Medical 80 
Council. Students sat one of four PSA ‘papers’ which had been standard-set using a modified Angoff 81 
process. 82 
Results. A total of 7,343 final-year medical students in all 31 UK medical schools sat the PSA. The overall 83 
pass rate was 95% with the pass rates for the individual papers ranging from 93 to 97%. The PSA was re-sat 84 
by 261 students who had failed and 80% of those candidates passed. The internal consistency (Cronbach’s 85 
alpha) of the four papers ranged from 0.74 to 0.77 (standard error of measurement 4.13 to 4.24%). There 86 
was a statistically significant variation in performance between medical school cohorts (F=32.6, p<0.001) 87 
and a strongly positive correlation in performance for individual schools between PSA2015 and PSA2016 88 
(r=0.79, 95% CI 0.61 to 0.90; p<0.01). 89 
Conclusions. PSA2016 demonstrated the feasibility of delivering a standardised national prescribing 90 
assessment online. The vast majority of UK final-year medical students were able to meet a pre-specified 91 
standard of prescribing competence. 92 
 93 
248 words (maximum 250) 94 
 95 
 96 
 97 
 98 
 99 
 100 
 101 
 102 
 103 
 104 
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Introduction 106 
Prescribing medicines is a core activity for the UK National Health Service (NHS), both in hospitals and 107 
primary care. Around 1 billion prescriptions are written annually in primary care in England, equating to an 108 
average of 20 for every member of the population [1]. Prescribing is a challenging task for any healthcare 109 
professional. Prescribers have to select the correct medicine, dosage, route, and frequency of 110 
administration, sometimes in the face of diagnostic uncertainty, taking into account potential individual 111 
variability in pharmacokinetics and response as a consequence of co-morbidity, genetics, and interacting 112 
drugs [2]. Given that individual patients have different ideas and expectations, and the outcome of any 113 
prescription is uncertain, the prescriber also needs to be able to counsel the patient and plan an 114 
appropriate strategy for monitoring and follow-up for evidence of benefit and/or harms. 115 
 116 
With these complexities, it is perhaps not surprising that poor prescribing is common. Recent studies found 117 
an error rate of 7–10% amongst prescriptions written by doctors in their first year of clinical practice while 118 
senior doctors, both in hospital and general practice, have a prescribing error rate of around 5% [3–5]. 119 
Several factors continuously add to the demands made on all prescribers including increased age and frailty 120 
of NHS patients, the growing complexity of treatment regimens, and an increasingly pressurised healthcare 121 
system.  122 
 123 
In these circumstances it is important that undergraduate medical education provides the training to 124 
ensure that new graduates meet minimum standards of prescribing competency. However, recent studies 125 
show that medical students and recent graduates often feel underprepared for and anxious about 126 
prescribing [6–9], a concern echoed by their supervisors [10,11] and the regulatory bodies [12]. Reliable 127 
evidence about prescribing competence is hard to find because relevant assessments have varied 128 
significantly between medical schools and none have been widely applied or validated [13]. 129 
 130 
In response to these concerns, the British Pharmacological Society (BPS) and Medical Schools Council 131 
Assessment (MSCA) developed the Prescribing Safety Assessment (PSA) as a summative assessment of 132 
Page 7 of 39
British Pharmacological Society
British Journal of Clinical Pharmacology
British Journal of Clinical Pharm
acology
 - 5 - 
knowledge, judgement and skills related to prescribing and supervising the use of medicines in a modern 133 
healthcare system [14]. The PSA is intended to enable final-year medical students at the end of their 134 
undergraduate training to demonstrate that they have achieved the necessary competence to prescribe, 135 
and supervise the use of, medicines at the standard expected of a Foundation (first- and second-year) 136 
doctor in the NHS. The PSA is based on the competencies identified by the UK General Medical Council in 137 
Outcomes for Graduates (2015) (originally published in Tomorrow’s Doctors (2009)) [15]. It is delivered 138 
online and is intended to assess, as far as possible within the confines of a virtual environment, complex 139 
skills including powers of deduction and problem solving that are relevant to the work of Foundation 140 
doctors. 141 
 142 
This report describes the process and outcomes of the PSA in 2016 (PSA2016) including the development of 143 
the assessment papers, the delivery of the PSA, the performance of the candidates and medical schools, 144 
and the basic psychometric properties of the assessment.  145 
 146 
 147 
  148 
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Methods 149 
 150 
Candidates 151 
Final-year medical students from all 31 UK medical schools were offered the opportunity to take the 152 
assessment. The PSA was originally piloted in 2012 and 2013, before being fully implemented in all schools 153 
in 2014 (PSA2014). Prior to 2016, a majority of medical schools hosted the PSA as a low-stakes formative 154 
assessment. For the first time in 2016, the postgraduate training committee representing the four UK 155 
countries stipulated that all new doctors entering postgraduate (Foundation) training, either from UK 156 
medical schools or overseas, would be required to take the PSA (those who failed would be expected to 157 
participate in enhanced supervision and remediation, and would be required to pass the PSA before the 158 
end of their first year of training). A further 828 students from seven international medical schools also 159 
participated in PSA2016 but they are not considered in this report. 160 
 161 
PSA structure 162 
The PSA comprises eight sections, each containing a specific item style reflecting different aspects of the 163 
process of prescribing, reviewing and advising about medicines: prescribing (PWS), prescription review 164 
(REV), planning management (MAN), providing information about medicines (COM), calculation skills (CAL), 165 
adverse drug reactions (ADR), drug monitoring (TDM) and data interpretation (DAT) (Figure 1). The 166 
different sections are intended to reflect not only the process of prescribing but also the related skills when 167 
supervising patients prescribed medicines by others. The question items are based on 60 patient scenarios 168 
that offer a total of 200 marks and candidates have two hours to complete the assessment. The scenarios 169 
relate to one of seven clinical settings: General Internal Medicine (MED), General Surgery (SURG), Elderly 170 
Care (ELD), Paediatrics (PED), Psychiatry (PSY), Obstetrics & Gynaecology (O&G), and General Practice (GP). 171 
 172 
The detailed breakdown of marks allocated to each section is shown in Table 1. Additional rules of 173 
assessment construction are that each PSA ‘paper’ must have a minimum item coverage in the various 174 
clinical settings (MED – 8, SURG – 4, ELD – 8, PED – 4, PSY – 4, O&G – 4, GP – 8) and have minimum 175 
coverage of high risk drugs (at least two items on each of the following: opioid analgesics, anticoagulants, 176 
insulin, antimicrobials and intravenous infusion fluids). The PSA does not carry negative marks. 177 
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 178 
 179 
Figure 1 here. Structure of the Prescribing Safety Assessment (PSA). 180 
Table 1 here. Allocation of question items and marks to each PSA section. 181 
 182 
 183 
PSA question items and papers 184 
PSA question items have been developed by a team of around one hundred trained authors (including 185 
clinical pharmacologists, other specialty and trainee doctors, general practitioners and pharmacists) who 186 
are mainly based in UK medical schools or NHS hospitals. Their question items undergo a strict 5-stage 187 
quality assurance process overseen by the PSA Assessment Board. Items that survived each stage of review, 188 
including a national peer-review meeting, were used to make four 60-item papers (A, B, C and D) 189 
conforming to the PSA blueprint [16]. The four papers included a total of 176 unique items with 32 190 
classified as ‘anchor’ items which were used in three of the four papers. There were 78 items repeated 191 
from PSA2015. The four papers were then ratified by the Assessment Board (two-day meeting, November 192 
2015), made available for standard-setting (two-day meeting, January 2016) and delivered to the 193 
candidates (February to June 2016).  194 
 195 
Standard-setting 196 
The pass marks for each paper were determined by the Standard-Setting Group comprising nine 197 
representatives from UK medical schools, who were selected for their knowledge of the appropriate 198 
minimum standard expected of Foundation year one doctors. The group used a modified Angoff method to 199 
derive the pass mark for each paper [17]. The meeting began with a discussion of, and agreement about, 200 
the attributes that would define the ‘just passing’ candidate. The group members then scored each item 201 
individually. To avoid ‘paper bias’, the order in which items were presented to group members was 202 
randomised. Those with outlying scores (‘hawks’ and ‘doves’), were asked to justify their scores, to inform a 203 
discussion about the item, before all members were asked to reconfirm or adjust their scores. The final 204 
mean scores across all group members for each item were used to calculate the pass mark for the 205 
paper. The derived pass marks for the four papers ranged from 62.0% to 65.5%. 206 
 207 
Candidate preparation  208 
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All candidates (final year medical students) were registered on the PSA online system and sent an e-mail 209 
requesting them to activate their accounts. After activation of their accounts they had access to general 210 
information about the PSA, 12 information videos and four 1-hour, 30-item, practice ‘papers’ with 211 
question-specific feedback. Candidates were encouraged to familiarise themselves with the different 212 
question types and the assessment environment and to practise finding information in the online version of 213 
the British National Formulary (BNF) [18]. 214 
 215 
Delivery of the PSA assessment events 216 
The PSA online delivery system allows the PSA team to create unique events specific to a date, a time slot, a 217 
school, a location and a specific cohort of students thus ensuring that candidates get the correct paper 218 
within a secure time envelope. PSA assessment events were run on four dates (01.02.16, 14.03.16, 219 
13.05.16, 01.06.16). The multiple dates enabled schools to schedule later events for cohorts who may have 220 
been absent on earlier days and to allow candidates who failed the opportunity to re-sit the PSA prior to 221 
graduation. Each PSA event was delivered live from a ‘cloud-based’ server to each event location under 222 
invigilated conditions. After logging into the PSA system on the day of the assessment candidates were 223 
given a unique event-specific password that allowed them to enter the 60-item assessment described 224 
above. Some examples of the assessment screens are shown in Figure 2. 225 
 226 
All candidates had access to the online BNF throughout the assessment. Candidates identified by their 227 
medical schools as normally being entitled to an extra time allowance were given an additional 30 minutes 228 
(25%) to complete the assessments and other reasonable adjustments as required by individual students 229 
were made. Assessment centres were provided with administrative and technical support during the events 230 
by staff at the MSCA office and the technical team (Rave Technologies). 231 
 232 
Figure 2 here. Example PSA question item screens: Prescribing (green), Prescription Review (blue), Planning 233 
Management (red), Calculation Skills (grey). 234 
 235 
 236 
Post-assessment review 237 
All prescriptions written by the candidates were scrutinised immediately after the assessment (‘post-238 
assessment review’) to ensure that the answer matrix for the prescribing (PWS) items took into account any 239 
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creditworthy responses that had not been anticipated and included in the mark scheme. The PSA system 240 
automatically identifies all unrecognised drugs and unrecognised drug order sentences provided by 241 
candidates during an event. These were carefully reviewed by the PSA Assessment Board and appropriate 242 
scores allocated and added to the electronic marking scheme. Candidates’ marks were automatically 243 
updated and the additions to the answer matrix are carried forward to subsequent uses of the item. The 244 
post-assessment review ensures that all candidates are marked in a fair and consistent way across event 245 
days. The performance of other item styles was also reviewed at this point for any unexpected answering 246 
behaviour. The final PSA results were released to medical schools within two weeks of each event and to 247 
the candidates shortly thereafter. 248 
 249 
Feedback 250 
After exiting the assessment on their computers, candidates were immediately presented with a standard 251 
feedback form designed to explore their views about the relevance and external validity of the assessment, 252 
their preparedness for taking it, the quality of the online delivery system and any other free text comments 253 
that they might wish to provide. The medical school PSA Leads were provided with a standard feedback 254 
form that allowed them to describe any administrative or process problems that they encountered. 255 
 256 
Statistical analysis 257 
Initial psychometric analysis was undertaken using classical test theory in both Excel and STATA v14. Data 258 
are presented as mean and standard deviation (SD) unless otherwise stated. For comparison between 259 
papers both raw and calibrated percentage scores are provided. Calibrated scores have been calculated 260 
using the pass mark for each paper, so that a raw score of 0% stays at 0%, a raw score equal to the pass 261 
mark becomes 50% and a raw score of 100% stays at 100%. Calibrated data were assumed to be sufficiently 262 
normally distributed to enable parametric statistical testing to be undertaken. One-way ANOVA was used 263 
to assess the significance of the variation between medical schools. Pearson rank correlation was used to 264 
measure the association between mean medical school performance in 2016 and 2015. Internal 265 
consistency of the papers was assessed using Cronbach’s alpha [19]. Standard error of measurement (SEM) 266 
was calculated using Cronbach’s alpha and the standard deviation of raw total scores for each paper [20]. 267 
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The item-rest correlation for individual question items was calculated using Pearson’s correlation between 268 
candidates’ scores on the item with their total score on all other items combined. 269 
  270 
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Results 271 
 272 
Candidate performance 273 
A total of 7,343 final-year students from 31 UK medical schools participated in PSA2016 and sat one of the 274 
four PSA ‘papers’ (A, B, C and D) in 200 PSA events held over four dates. Data from 254 students from one 275 
school that experienced considerable technical difficulties (where all candidates were allowed an additional 276 
30 minutes in which to complete the assessment) were excluded from analysis. The following data 277 
summarises the performance of the remaining 7,089 candidates. 278 
 279 
The mean raw scores (SD) for the four papers ranged from 80.0% (8.3%) on Paper A to 76.1% (8.8%) on 280 
Paper D with an overall pass rate of 95% (compared to 91% in PSA2015 and 94% in PSA2014) (Table 2).  281 
The range in pass rates for the individual papers was from 97.2% (Paper A) to 92.6% (Paper D). The pass 282 
rate amongst the 286 students re-sitting the PSA was 80% meaning that less than one percent of all UK 283 
students failed to pass the PSA by the end of the academic year. 284 
 285 
Reasonable adjustment in the form of allocation of extra time was provided to 693 candidates (9.8%). The 286 
first-sitting pass rate amongst students with extra time was 94%, compared to 95% among students 287 
without extra time (chi-squared=2.31, p=0.128). The mean (SD) calibrated score amongst students with 288 
extra time was 70.5% (11.8%), compared with 71.5% (11.3%) for those without extra time (t=2.20, 289 
p<0.001). 290 
 291 
When the individual sections of the PSA were considered separately, candidates appeared to do 292 
particularly well on the adverse drug reactions items (median section score on each paper 88%) and less 293 
well on the data interpretation items (median section score on each paper 67%) when compared to the 294 
overall paper (median scores 77 to 81%). A potential reason for the relatively poor performance on the 295 
latter section (which was also noted in PSA2015) is that data interpretation items are presented as the last 296 
section of the assessment and some candidates may be running out of time when these items are 297 
attempted (although questions can be attempted in any order). 298 
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 299 
The 32 anchor items were distributed such that eight items were used for each combination of three 300 
papers. The mean percentage scores achieved by candidates across the eight repeated items in each set of 301 
papers were ABC (74.7 to 76.7%), ABD (76.9 to 78.2%), ACD (76.3 to 77.1%) and BCD (81.5 to 82.1%) 302 
suggesting that there were only relatively small differences in performance of the cohorts attempting each 303 
paper.  304 
 305 
Some items have been used in two or three of the assessment diets run over the last four years (2013 to 306 
2016). For the 16 items used in 2013 and 2016 the total absolute improvement in mean item score was 307 
11.7 percentage points. For the 40 items used in 2014 and 2016 the improvement was 1.1 percentage 308 
points and for the 78 items used in 2015 and 2016 it was 2.6 percentage points. 309 
 310 
Table 2 here. Candidate performance in PSA2016. 311 
 312 
Internal consistency 313 
The mean Cronbach’s alpha across the four papers was 0.75 (range 0.74 to 0.77) and the standard error of 314 
measurement was 4.19% (range 4.17 to 4.24%) (Table 2). The Cronbach’s alpha was almost identical to the 315 
0.76 achieved in PSA2015 and above the 0.70 achieved in PSA2014. Using classical test theory 52% of items 316 
showed good discrimination, with an item-rest correlation greater than 0.2 while 9% had an item-rest 317 
correlation less than 0.1. 318 
 319 
Performance by medical school 320 
The number of students taking the PSA at each school ranged from 47 to 430. Comparison of the 321 
performance of schools that took different papers was facilitated by calibrating the raw scores so that the 322 
pass mark was considered to be 50% for each. The mean calibrated scores across schools ranged from 323 
63.2% to 78.2% (Figure 3). The result of a one-way ANOVA comparing mean student scores was F29,7059 = 324 
32.6, p<0.001, indicating statistically significant differences in performance between schools.   325 
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 326 
There was a strong positive correlation between the mean medical school scores recorded in PSA2015 and 327 
PSA2016 (Figure 4). The Pearson’s correlation coefficient for 2015 to 2016 was 0.79 (95% CI 0.61 to 0.90; 328 
p<0.01). Mean scores improved between 2015 and 2016 at all but two schools. The variability across 329 
schools did reduce slightly, with standard deviations of mean scores (coefficients of variation) of 4.11% 330 
(0.061) in 2015 and 3.84% (0.054) in 2016. 331 
 332 
Figure 3. Performance by medical school. 333 
Figure 4. Mean calibrated score by medical school in 2015 and 2016. 334 
 335 
 336 
 337 
 338 
  339 
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 340 
Discussion 341 
Although medical schools and NHS hospitals had previously developed local prescribing assessments, there 342 
has never been a widely accepted measure of prescribing performance in medical education. Our intention 343 
was to develop a reliable and valid national prescribing assessment that might serve to enable medical 344 
students (and their medical schools) to demonstrate that they had achieved a basic standard of prescribing 345 
competence by the time of graduation. In addition, we hoped that the PSA might increase the visibility of 346 
prescribing in the curriculum, promote better training experiences, and provide some feedback about the 347 
impact of varying education strategies. This might, in turn, raise and unify prescribing standards and 348 
ultimately contribute to enhanced quality and safety of patient care. 349 
 350 
The PSA is the first national online prescribing assessment for final-year medical students. Since its original 351 
conception in 2010 it has become an annual part of the assessment cycle in all UK medical schools and is 352 
supported by a dedicated editorial team, a national panel of authors drawn from academia and the NHS, an 353 
Assessment Board responsible for a multi-stage quality assurance process, a Standard-Setting Sub-Group 354 
and a technical team responsible for maintaining and improving the online delivery system. The key points 355 
from this report of PSA2016 are that: (i) the overall performance of the candidates was good, (ii) there is 356 
some evidence that performance is improving, (iii) the reliability of the assessment is improving, and (iv) 357 
there is significant variation in the performance of students from different medical schools. 358 
 359 
Candidate performance 360 
The vast majority of final-year students were able to pass the PSA, meeting the standard of competence 361 
pre-defined by the Angoff-derived pass mark, and most of those who failed were able to pass the PSA after 362 
a period of revision and remediation. The pass rate of 95% represented an improvement on previous years 363 
(compared to 91% in PSA2015 and 94% in PSA2014), which might represent a progressive improvement in 364 
performance. However, there may be other relevant factors. It is possible that the 2016 papers were easier 365 
relative to pass mark even though the standard-setters followed the same process and definitions. The 366 
announcement by the Foundation Programme that all entrants would be expected to have taken the PSA 367 
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(and pass it by the end of their first year of training at the latest) undoubtedly raised the stakes for the 368 
students and might have increased the overall motivation of the candidates. This change would be 369 
particularly relevant for the majority of medical schools where taking the PSA was previously used as a 370 
formative assessment. There was also more support available for candidates than in previous years with 371 
four practice papers and 12 online videos describing the process and structure of the PSA. Some of the 372 
PSA2016 cohort also had experience of local ‘mock’ PSA events during their penultimate year of study in 373 
2015. Anecdotal reports indicate that some medical schools had developed additional learning sessions 374 
focused on prescribing in an effort to prepare their students for the PSA. The better performance of 375 
candidates on items repeated over the years 2013 to 2016 and the slightly reduced variability in 376 
performance between medical schools also supports the belief that there is a genuine improvement in 377 
performance. 378 
 379 
Although the performance of the candidates is generally good, and seems to be improving, we hope that 380 
further improvements might be achieved. Part of that process will involve identifying some of the common 381 
mistakes and misunderstandings demonstrated by candidates and providing detailed feedback to medical 382 
schools. This should support the improvement of teaching and learning of prescribing amongst future 383 
cohorts. A final point to make is that the Angoff standard-setting process used to define competence 384 
remains a subjective and imprecise prediction, even if carefully executed [21]. It is dependent on the 385 
interpretation of the definition of the ‘just passing’ candidate by each of the PSA standard-setters and how 386 
relevant the definition is to safe clinical practice and the risk of error. This uncertainty requires further 387 
exploration. 388 
 389 
Reliability 390 
The position of the PSA as a progressively high-stakes assessment of safe practice increases the focus on its 391 
reliability. The analysis of internal consistency showed that the mean Cronbach’s alpha was 0.75, which was 392 
similar to PSA2015 (0.76) and higher than PSA2014 (0.70). Although this remains below the 0.8 that some 393 
have suggested to be the minimum acceptable reliability for a high stakes test [22], it compares well with 394 
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other multi-domain assessments limited to only two hours duration [23]. Indeed, others recommend 395 
acceptance of a lower alpha value (0.70) to ensure that the reliability of an assessment does not come at 396 
the expense of validity (i.e. high reliability would be achieved by assessing a narrow range of skills and areas 397 
of knowledge rather than sampling from the entire skill set required for safe prescribing) [24]. The 398 
Spearman-Brown formula predicts that the number of items in each section of the PSA would need to be 399 
increased by around 25% to achieve a reliability of 0.8, a change that might threaten the acceptability of 400 
the assessment. While we hope that the current reliability estimates will maintain support for the process, 401 
the PSA aims to identify and preserve the most discriminating question items, reject those that perform 402 
less well and provide constructive feedback to our item authors. 403 
 404 
Medical school variation 405 
There was a significant variation in the performance of final-year students studying in different medical 406 
schools and the performance in 2015 and 2016 was strongly correlated, implying that this is a real and 407 
consistent effect. There are a number of possible reasons for this variation. It might represent a genuine 408 
variation in the knowledge, skills and judgement that are the intended focus of the assessment. Previous 409 
reviews have suggested that there are variations in undergr duate training, visibility, emphasis and 410 
assessments in clinical pharmacology and prescribing [13]. These variations were one of the reasons why 411 
the Safe Prescribing Working Group previously recommended the need for the development of a clear 412 
description of relevant learning outcomes [15,25,26], and access to nation l eLearning support materials 413 
[27]. The variation may also represent more general differences in the aptitudes of the cohorts such as 414 
their ability to perform in high-stakes time-pressured assessments. A similar inter-school variation has been 415 
noted in other assessments such as subsequent performance in specific postgraduate examinations [28]. 416 
There may also be more subtle factors at play such as the timing of the assessments in relation to the local 417 
undergraduate curriculum, involvement of local teachers in the PSA process and the general enthusiasm 418 
and support for national assessments in general or the PSA in particular. 419 
 420 
Important limitations 421 
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There are some important inherent limitations in developing and implementing the PSA as a national 422 
prescribing assessment. Foremost is the lack of a demonstrable association between performance in its 423 
controlled environment and prescribing competence in the real world of clinical practice. This question 424 
must be addressed but poses significant difficulties, primarily because of the lack of an easily applied 425 
measure of real life performance, the inherent variability of case mix in clinical practice and numerous 426 
other factors that influence individual practice (e.g. workload, supervision). 427 
 428 
There are always potential technical risks in delivering live online assessments. Although major problems 429 
have been rare in our experience, network slowing can cause problems (e.g. slow page loading, slow item 430 
turnover, screen freezes) at peak times involving several thousand candidates. These problems severely 431 
affected one site involved in PSA2016 although online delivery from the ‘cloud’ means that candidate 432 
answers are not lost, even when connections fail.  433 
 434 
A frequent concern expressed by the candidates is the timing of the assessment. Keystroke logs suggest 435 
that almost all candidates remain active throughout the two-hour duration of the assessment. While some 436 
candidates feedback that ‘patient safety tasks should never be rushed’ the reality of clinical practice is that 437 
time is often limited by workload pressures. Furthermore, the PSA is an open-book assessment during 438 
which all candidates have access to the BNF. The BNF cannot answer all questions but provides a valuable 439 
back up to support the candidates’ knowledge. The time limit places a premium on being able to use the 440 
BNF efficiently but does not allow reliance on the reference source to override the requirement for basic 441 
knowledge and clinical judgement gained through clinical training. 442 
 443 
The pass mark is relatively low for a high-stakes assessment. This reflects the fact that those items with the 444 
best discrimination tend to have a facility mid-way between guessing and maximum [29,30]. This highlights 445 
the tension between having an easier assessment composed of ‘must-know’ items with high facility and 446 
one that can more reliably differentiate candidates at the pass-fail cut score. 447 
 448 
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Future issues 449 
A standardised tool for assessing prescribing competence might be deployed more widely than 450 
undergraduate medical education. Most doctors prescribe frequently throughout their careers and, like 451 
doctors in their first year of clinical practice, often make errors [3–5]. Since optimal prescribing practice 452 
changes frequently, an assessment of prescribing would also be highly relevant to postgraduate training 453 
and revalidation. Indeed, it might be argued that prescribing should feature prominently as an identifiable 454 
component of any broad assessment of competence to practise medicine. This will be an important 455 
consideration for the General Medical Council in its consultation about the structure of the new Medical 456 
Licensing Examination (MLA) [31]. Although identifying prescribing so clearly might run contrary to the 457 
current focus on integrated learning and assessment, we believe that it deserves such prominence. Few 458 
activities are undertaken so frequently by doctors, carry such immediate implications for patient health 459 
outcomes [32], have such clearly documented rates of error in modern healthcare [3–5], or carry such a 460 
clear training-practice deficit [12]. 461 
 462 
Prescribing rights have now been extended to other prescribing groups (e.g. nurse practitioners, 463 
pharmacists) [33]. In recognition of this broadened definition of a ‘prescriber’ a national prescribing 464 
competency framework has been developed that identifies the generic abilities that should be possessed 465 
by all prescribing professionals [34], many of which feature in the PSA. Some early pilot work has been 466 
started to explore the utility of the PSA amongst other professional groups [35].  467 
 468 
A final consideration is whether the PSA will contribute to improved prescribing outcomes. It is well 469 
recognised that assessments influence learner and institutional priorities [36]. In this way the PSA is 470 
undoubtedly increasing the visibility of medicines safety as an outcome for graduates. As anticipated, 471 
evidence of ‘teaching to the test’ is emerging, so it is critical that the PSA remains firmly relevant t  clinical 472 
practice. The candidate feedback suggests that the assessment is relevant to their training needs and that 473 
the chance to get feedback on their performance is welcomed. We believe that this initiative is beginning to 474 
deliver graduates who are better prepared to face the challenges of prescribing and supervising the use of 475 
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medicines in the NHS. However, that gain can only be part of a wider drive to improve patient outcomes, 476 
which will also include better supervision and team-working, point of care decision support, improved 477 
prescribing systems and avoiding unsustainable individual workloads [3,4,14]. 478 
 479 
Conclusion 480 
The PSA is now a major national collaboration involving all UK medical schools. The annual scale of the PSA 481 
process (academic, administrative and technical) is now considerable: around 8,500 students from the UK 482 
and overseas, 17,000 candidate hours of assessment and over half a million patient safety-related 483 
questions posed and marked (including 70,000 prescriptions). The PSA is beginning to meet many of its 484 
initial objectives in providing a more reliable and consistent assessment of prescribing competence at 485 
graduation as well as stimulating increased visibility in this key part of undergraduate training. The future of 486 
the PSA must involve ongoing efforts to maximise its quality, reliability and external validity. 487 
 488 
 489 
 490 
 491 
 492 
 493 
 494 
 495 
  496 
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TABLES 619 
 620 
 621 
 622 
 623 
 624 
 625 
 626 
 627 
 628 
Section Description Marks Question items 
1 Prescribing (PWS) 80 8 items of 10 marks each 
2 Prescription Review (REV) 32 8 items of 4 marks each 
3 Planning Management (MAN) 16 8 items of 2 marks each 
4 Providing Information (COM) 12 6 items of 2 marks each 
5 Calculation Skills (CAL) 16 8 items of 2 marks each 
6 Adverse Drug Reactions (ADR) 16 8 items of 2 marks each 
7 Drug Monitoring (TDM) 16 8 items of 2 marks each 
8 Data Interpretation (DAT) 12 6 items of 2 marks each 
 TOTAL MARKS 200  
 629 
 630 
 631 
Table 1. Allocation of question items and marks to each PSA section. 632 
 633 
  634 
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 635 
 636 
 637 
 638 
 639 
 640 
 641 
 Paper A Paper B Paper C Paper D 
Angoff pass mark (%) 62.0 65.5 63.0 63.0 
Candidates 1,914* 1,869 1,746 1,560 
Medical schools 20 16 16 17 
Pass rate (%) 97.2 94.0 95.8 92.6 
RAW SCORES (%)     
Mean (SD) 80.0 (8.3) 79.8 (8.5) 78.3 (8.2) 76.1 (8.8) 
Median (IQR) 
81.0  
(75.0 to 86.0) 
81.0  
(75.0 to 86.0) 
79.0  
(73.5 to 84.5) 
77.0  
(71.0 to 82.5) 
Range 36.5 to 97.5 38.0 to 97.5 32.0 to 98.5 34.0 to 95.5 
CALIBRATED SCORES (%)     
Mean (SD) 73.8 (10.7) 70.9 (11.6) 70.8 (10.7) 68.0 (11.2) 
Median (IQR) 
75.0  
(67.1 to 81.6) 
72.5  
(63.8 to 79.7) 
71.6  
(64.2 to 79.1) 
68.9  
(60.8 to 76.4) 
Range 29.4 to 96.7 29.0 to 96.4 25.4 to 98.0 27.0 to 93.9 
Cronbach’s alpha 0.738 0.756 0.743 0.767 
SEM (%) 4.24 4.17 4.13 4.23 
 642 
 643 
 644 
Table 2. Candidate performance in PSA2016. * A further 254 candidates at one school sat Paper A but 645 
experienced significant technical difficulties and are not included in this analysis. Their pass rate (97.6%) 646 
was similar to the remainder of the candidates sitting Paper A.  647 
SD: Standard deviation, IQR: Inter-quartile range; SEM: Standard error of measurement 648 
 649 
  650 
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Legends to figures 651 
 652 
Figure 1. Standard structure of the Prescribing Safety Assessment. 653 
 654 
Figure 2. Example PSA question item screens: Prescribing (green), Prescription Review (blue), Planning 655 
Management (red), Calculation Skills (grey). 656 
 657 
Figure 3. Candidate performance by medical school. 658 
 659 
Figure 4. Mean calibrated score by medical school in 2015 and 2016.  660 
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Figures 661 
 662 
 663 
 664 
 665 
 666 
 667 
 668 
Figure 1. Standard structure of the Prescribing Safety Assessment. 669 
 670 
 671 
 672 
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 674 
 675 
 676 
 677 
 678 
 679 
 680 
 681 
 682 
 683 
Figure 2. Example PSA question item screens: Prescribing (green), Prescription Review (blue), Planning 684 
Management (red), Calculation Skills (grey). 685 
 686 
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 688 
 689 
 690 
 691 
 692 
 693 
 694 
 695 
 696 
 697 
 698 
 699 
 700 
 701 
 702 
 703 
 704 
 705 
 706 
 707 
 708 
 709 
 710 
 711 
 712 
 713 
 714 
 715 
 716 
 717 
 718 
Figure 3. Candidate performance by medical school. The red horizontal line indicates the pass mark 719 
following calibration and the green horizontal line the median score across medical schools. 720 
 721 
  722 
Page 33 of 39
British Pharmacological Society
British Journal of Clinical Pharmacology
British Journal of Clinical Pharm
acology
 - 31 - 
 723 
 724 
 725 
 726 
 727 
 728 
 729 
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 734 
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 757 
Figure 4. Mean calibrated score by medical school in 2015 and 2016. 758 
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Prescribing Safety Assessment 2016: Delivery of a national prescribing assessment to 7,343 UK 
final-year medical students – Maxwell et al. 
 
Table 1 
 
 
 
 
 
 
 
Section Description Marks Question items 
1 Prescribing (PWS) 80 8 items of 10 marks each 
2 Prescription Review (REV) 32 8 items of 4 marks each 
3 Planning Management (MAN) 16 8 items of 2 marks each 
4 Providing Information (COM) 12 6 items of 2 marks each 
5 Calculation Skills (CAL) 16 8 items of 2 marks each 
6 Adverse Drug Reactions (ADR) 16 8 items of 2 marks each 
7 Drug Monitoring (TDM) 16 8 items of 2 marks each 
8 Data Interpretation (DAT) 12 6 items of 2 marks each 
 TOTAL MARKS 200  
 
 
 
Table 1. Allocation of question items and marks to each PSA section. 
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Prescribing Safety Assessment 2016: Delivery of a national prescribing assessment to 7,343 UK 
final-year medical students – Maxwell et al. 
 
Table 2 
 
 
 
 
 
 Paper A Paper B Paper C Paper D 
Angoff pass mark (%) 62.0 65.5 63.0 63.0 
Candidates 1,914* 1,869 1,746 1,560 
Medical schools 20 16 16 17 
Pass rate (%) 97.2 94.0 95.8 92.6 
RAW SCORES (%)     
Mean (SD) 80.0 (8.3) 79.8 (8.5) 78.3 (8.2) 76.1 (8.8) 
Median (IQR) 
81.0  
(75.0 to 86.0) 
81.0  
(75.0 to 86.0) 
79.0  
(73.5 to 84.5) 
77.0  
(71.0 to 82.5) 
Range 36.5 to 97.5 38.0 to 97.5 32.0 to 98.5 34.0 to 95.5 
CALIBRATED SCORES (%)     
Mean (SD) 73.8 (10.7) 70.9 (11.6) 70.8 (10.7) 68.0 (11.2) 
Median (IQR) 
75.0  
(67.1 to 81.6) 
72.5  
(63.8 to 79.7) 
71.6  
(64.2 to 79.1) 
68.9  
(60.8 to 76.4) 
Range 29.4 to 96.7 29.0 to 96.4 25.4 to 98.0 27.0 to 93.9 
Cronbach’s alpha 0.738 0.756 0.743 0.767 
SEM (%) 4.24 4.17 4.13 4.23 
 
 
 
Table 2. Candidate performance in PSA2016. * A further 254 candidates at one school sat Paper A but 
experienced significant technical difficulties and are not included in this analysis. Their pass rate (97.6%) 
was similar to the remainder of the candidates sitting Paper A.  
SD: Standard deviation, IQR: Inter-quartile range; SEM: Standard error of measurement 
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Prescribing Safety Assessment 2016: Delivery of a national prescribing assessment to 7,343 UK 
final-year medical students – Maxwell et al. 
 
Figure 1 
 
 
 
 
 
 
 
 
Figure 1. Standard structure of the Prescribing Safety Assessment. 
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Prescribing Safety Assessment 2016: Delivery of a national prescribing assessment to 7,343 UK 
final-year medical students – Maxwell et al. 
 
Figure 2 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Example PSA question item screens: Prescribing (green), Prescription Review (blue), Planning 
Management (red), Calculation Skills (grey). 
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Prescribing Safety Assessment 2016: Delivery of a national prescribing assessment to 7,343 UK 
final-year medical students – Maxwell et al. 
 
Figure 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Candidate performance by medical school. The red horizontal line indicates the pass mark 
following calibration and the green horizontal line the median score across medical schools. 
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Prescribing Safety Assessment 2016: Delivery of a national prescribing assessment to 7,343 UK 
final-year medical students – Maxwell et al. 
 
Figure 4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Mean calibrated score by medical school in 2015 and 2016. 
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